Glenview Trust co Has $2.72 Million Stake in Waters Co. (NYSE:WAT)

Glenview Trust co lowered its holdings in shares of Waters Co. (NYSE:WAT) by 13.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,337 shares of the medical instruments supplier’s stock after selling 1,100 shares during the quarter. Glenview Trust co’s holdings in Waters were worth $2,722,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. Bank of Jackson Hole Trust bought a new position in Waters in the fourth quarter valued at approximately $34,000. Fortitude Family Office LLC boosted its stake in Waters by 235.7% in the 4th quarter. Fortitude Family Office LLC now owns 94 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 66 shares during the period. Steward Partners Investment Advisory LLC increased its holdings in Waters by 129.3% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 94 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 53 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Waters by 54.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 125 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 44 shares during the period. Finally, R Squared Ltd bought a new stake in shares of Waters in the fourth quarter valued at about $63,000. Institutional investors own 94.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. JPMorgan Chase & Co. increased their price objective on Waters from $380.00 to $390.00 and gave the stock a “neutral” rating in a report on Thursday, March 6th. Scotiabank raised shares of Waters from a “sector perform” rating to a “sector outperform” rating and boosted their price objective for the stock from $430.00 to $450.00 in a research report on Thursday, February 13th. Barclays raised shares of Waters from an “underweight” rating to an “equal weight” rating and raised their target price for the company from $360.00 to $415.00 in a research report on Monday, February 10th. Wells Fargo & Company increased their price objective on shares of Waters from $415.00 to $420.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Finally, UBS Group lifted their target price on Waters from $405.00 to $410.00 and gave the company a “neutral” rating in a research report on Thursday, February 13th. Eleven research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Waters has an average rating of “Hold” and an average price target of $391.07.

Waters Stock Up 3.8 %

WAT opened at $378.18 on Monday. The stock has a fifty day moving average of $391.24 and a 200-day moving average of $370.48. The company has a market capitalization of $22.47 billion, a P/E ratio of 35.31, a P/E/G ratio of 3.79 and a beta of 1.00. Waters Co. has a fifty-two week low of $279.24 and a fifty-two week high of $423.56. The company has a debt-to-equity ratio of 1.14, a quick ratio of 0.65 and a current ratio of 0.94.

Waters (NYSE:WAT) last posted its quarterly earnings data on Wednesday, February 12th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.02 by $0.08. Waters had a net margin of 21.56% and a return on equity of 46.31%. On average, equities analysts expect that Waters Co. will post 12.86 EPS for the current year.

Waters Profile

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.